BioCentury | Jul 24, 2020
Regulation

Data Bytes: CHMP’s July recommendations

Among the 11 new medicines recommended for approval by EMA’s CHMP is the first antibody-drug conjugate, and most advanced BCMA-targeted agent, for multiple myeloma patients: GSK’s Blenrep belantamab mafodotin. FDA’s Oncologic Drugs Advisory Committee unanimously...
BioCentury | Jun 12, 2020
Product Development

June 11 Quick Takes: Sobi licenses Selecta gout therapy; plus Viela’s first approval, CSL, BMS, Sirnaomics’ spinout, Denali-Sanofi

Sobi pays $100M up front for Selecta therapy Swedish Orphan Biovitrum AB (SSE:SOBI) licensed ex-China rights to SEL-212, a gout therapy from Selecta Biosciences Inc. (NASDAQ:SELB). Selecta will receive $75 million up front and $25...
BioCentury | Mar 19, 2020
Product Development

Roivant pivots towards ARDS in COVID-19; plus Italian studies of repurposed anti-inflammatories, vaccine updates and more

Wednesday saw a full slate of clinical updates across the globe for vaccine and therapeutic candidates to address COVID-19, while HHS launched a new public-private partnership to ramp up emergency drug packaging capabilities. Roivant Sciences...
BioCentury | Jan 8, 2020
Company News

Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone

Fred Hutchinson Cancer Research Center hired Thomas Lynch as president and director, effective next month. Lynch was CSO of Bristol-Myers Squibb Co. (NYSE:BMY). He succeeds Gary Gilliland, who announced in September his plans to step...
BioCentury | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

Rare metabolic disease company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) said Keith Gottesdiener will step down as CEO, president and a board member after more than eight years. He will stay on through the company’s submission of...
BioCentury | Oct 23, 2019
Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

Amgen Inc. (NASDAQ:AMGN) said EVP and CFO David Meline will retire at year end. The pharma hired Peter Griffith as EVP, finance and said he will succeed Meline as CFO on Jan. 1. Griffith was...
BioCentury | Sep 30, 2019
Company News

Sobi adding to U.S. presence, hematology pipeline via $915M Dova takeout

With the $915 million takeout of Dova Pharmaceuticals and a co-development deal with Sanofi in hemophilia, Sobi is continuing its push into the U.S. and strengthening its presence in hematology. Swedish Orphan Biovitrum AB (SSE:SOBI)...
BioCentury | Sep 20, 2019
Politics & Policy

Legislation would make pediatric Priority Review voucher program permanent

Members of the congressional Childhood Cancer Caucus have introduced legislation that would reauthorize the Creating Hope Act, making permanent the FDA’s rare pediatric disease Priority Review voucher program. Reps. G.K. Butterfield (D-N.C.), Mike Kelly (R-Penn.),...
BioCentury | Aug 23, 2019
Company News

Aug. 22 Company Quick Takes: Innovent, Lilly in biologics deal; plus Sobi, Gilead, Themis-Merck, Iconic-Novartis, GW, BeiGene, Clearside, Inex Innovations

Innovent, Lilly in third biologics deal Innovent Biologics Inc. (HKEX:1801) in-licensed Chinese rights to OXM3 from Eli Lilly and Co. (NYSE:LLY) to treat diabetes. The oxyntomodulin analog -- a dual agonist of GLP-1R and GCGR...
BioCentury | Jun 13, 2019
Company News

Sobi buying Novimmune assets as it refocuses R&D

Less than a year after gaining an exclusive worldwide license for Gamifant emapalumab from Novimmune, Sobi is acquiring a newco formed around the hematology therapy for CHF515 million ($519.2 million) and restructuring its R&D pipeline...
Items per page:
1 - 10 of 631
BioCentury | Jul 24, 2020
Regulation

Data Bytes: CHMP’s July recommendations

Among the 11 new medicines recommended for approval by EMA’s CHMP is the first antibody-drug conjugate, and most advanced BCMA-targeted agent, for multiple myeloma patients: GSK’s Blenrep belantamab mafodotin. FDA’s Oncologic Drugs Advisory Committee unanimously...
BioCentury | Jun 12, 2020
Product Development

June 11 Quick Takes: Sobi licenses Selecta gout therapy; plus Viela’s first approval, CSL, BMS, Sirnaomics’ spinout, Denali-Sanofi

Sobi pays $100M up front for Selecta therapy Swedish Orphan Biovitrum AB (SSE:SOBI) licensed ex-China rights to SEL-212, a gout therapy from Selecta Biosciences Inc. (NASDAQ:SELB). Selecta will receive $75 million up front and $25...
BioCentury | Mar 19, 2020
Product Development

Roivant pivots towards ARDS in COVID-19; plus Italian studies of repurposed anti-inflammatories, vaccine updates and more

Wednesday saw a full slate of clinical updates across the globe for vaccine and therapeutic candidates to address COVID-19, while HHS launched a new public-private partnership to ramp up emergency drug packaging capabilities. Roivant Sciences...
BioCentury | Jan 8, 2020
Company News

Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone

Fred Hutchinson Cancer Research Center hired Thomas Lynch as president and director, effective next month. Lynch was CSO of Bristol-Myers Squibb Co. (NYSE:BMY). He succeeds Gary Gilliland, who announced in September his plans to step...
BioCentury | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

Rare metabolic disease company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) said Keith Gottesdiener will step down as CEO, president and a board member after more than eight years. He will stay on through the company’s submission of...
BioCentury | Oct 23, 2019
Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

Amgen Inc. (NASDAQ:AMGN) said EVP and CFO David Meline will retire at year end. The pharma hired Peter Griffith as EVP, finance and said he will succeed Meline as CFO on Jan. 1. Griffith was...
BioCentury | Sep 30, 2019
Company News

Sobi adding to U.S. presence, hematology pipeline via $915M Dova takeout

With the $915 million takeout of Dova Pharmaceuticals and a co-development deal with Sanofi in hemophilia, Sobi is continuing its push into the U.S. and strengthening its presence in hematology. Swedish Orphan Biovitrum AB (SSE:SOBI)...
BioCentury | Sep 20, 2019
Politics & Policy

Legislation would make pediatric Priority Review voucher program permanent

Members of the congressional Childhood Cancer Caucus have introduced legislation that would reauthorize the Creating Hope Act, making permanent the FDA’s rare pediatric disease Priority Review voucher program. Reps. G.K. Butterfield (D-N.C.), Mike Kelly (R-Penn.),...
BioCentury | Aug 23, 2019
Company News

Aug. 22 Company Quick Takes: Innovent, Lilly in biologics deal; plus Sobi, Gilead, Themis-Merck, Iconic-Novartis, GW, BeiGene, Clearside, Inex Innovations

Innovent, Lilly in third biologics deal Innovent Biologics Inc. (HKEX:1801) in-licensed Chinese rights to OXM3 from Eli Lilly and Co. (NYSE:LLY) to treat diabetes. The oxyntomodulin analog -- a dual agonist of GLP-1R and GCGR...
BioCentury | Jun 13, 2019
Company News

Sobi buying Novimmune assets as it refocuses R&D

Less than a year after gaining an exclusive worldwide license for Gamifant emapalumab from Novimmune, Sobi is acquiring a newco formed around the hematology therapy for CHF515 million ($519.2 million) and restructuring its R&D pipeline...
Items per page:
1 - 10 of 631